<DOC>
	<DOCNO>NCT02040987</DOCNO>
	<brief_summary>A thorough QT study AZD3293</brief_summary>
	<brief_title>AZD3293 Thorough QT Study Healthy Male Volunteers</brief_title>
	<detailed_description>A Single-Center , Randomized , Double-Blinded , Placebo-Controlled , 4-way Cross-over Study Assess Effect Single Oral Dose AZD3293 Administration QTc Interval Compared Placebo , Using Open-Label AVELOX ( moxifloxacin ) Positive Control , Healthy Male Subjects</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Provision sign , write date informed consent prior studyspecific procedure 2 . Healthy male subject must able understand willing comply study procedure , restriction requirement 3 . Healthy male subject age 18 55 year 4 . Body weight ≥ 50 ≤ 100 kg body mass index ( BMI ) ≥19 ≤30 5 . Clinically normal finding physical examination relation age , judge investigator . 1 . History clinically significant disease disorder may either put subject risk participation study , influence result subject 's ability participate study 2 . History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug 3 . History previous ongoing psychiatric disease/condition include psychosis , affective disorder , anxiety disorder , borderline state personality disorder 4 . History neurologic disease , include seizure ( exception febrile infantile seizure ) , recent memory impairment clinically significant head injury 5 . History psychotic disorder among first degree relative</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Thorough QT study</keyword>
</DOC>